BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period for schizophrenia
This study is completed in the United States, in Australia, in France, .... It is testing BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period for schizophrenia.
SchizophreniaDrugFrom 18 Years to 50 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Australia, in Canada, and in France.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: April 15, 2019
Recruitment status
Completed
Enrollment listed in the registry
200
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Australia, France, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT03859973
Official title
A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03859973. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Australia · 4 sites
Lyell McEwin Hospital
Elizabeth Vale, South Australia
Site status: Not listed — confirm with the team
Monash Medical Centre
Clayton, Victoria
Site status: Not listed — confirm with the team
St Vincent's Hospital Melbourne
Fitzroy, Victoria
Site status: Not listed — confirm with the team
Monash Alfred Psychiatry Research Centre
Melbourne, Victoria
Site status: Not listed — confirm with the team
Canada · 4 sites
University of Calgary
Calgary, Alberta
Site status: Not listed — confirm with the team
BC Mental Health and Addictions Research Institute (University of British Columbia)
Vancouver, British Columbia
Site status: Not listed — confirm with the team
Centre for Addiction and Mental Health (CAMH)
Toronto, Ontario
Site status: Not listed — confirm with the team
IUSMM Institut Universitaire en Sante Mentale de Montreal
Montreal, Quebec
Site status: Not listed — confirm with the team
France · 8 sites
CTR Esquirol
Caen
Site status: Not listed — confirm with the team
HOP Dijon-Bourgogne
Dijon
Site status: Not listed — confirm with the team
CAB Médical Psyché
Douai
Site status: Not listed — confirm with the team
HOP la Colombière
Montpellier
Site status: Not listed — confirm with the team
HOP Saint-Jacques
Nantes
Site status: Not listed — confirm with the team
HOP Pasteur
Nice
Site status: Not listed — confirm with the team
GHU Paris Psychiatrie et Neurosciences
Paris
Site status: Not listed — confirm with the team
HOP Nord
Saint-Priest-en-Jarez
Site status: Not listed — confirm with the team
New Zealand · 1 site
North Shore Hospital, Takapuna
Takpuna Auckland
Site status: Not listed — confirm with the team
United Kingdom · 5 sites
The Fritchie Centre
Cheltenham
Site status: Not listed — confirm with the team
Royal Edinburgh Hospital
Edinburgh
Site status: Not listed — confirm with the team
Queen Elizabeth University Hospital
Glasgow
Site status: Not listed — confirm with the team
Maudsley Hospital
London
Site status: Not listed — confirm with the team
Warneford Hospital
Oxford
Site status: Not listed — confirm with the team
United States · 28 sites
Atria Clinical Research
Little Rock, Arkansas
Site status: Not listed — confirm with the team
Woodland Research Northwest
Rogers, Arkansas
Site status: Not listed — confirm with the team
Encino Hospital Medical Center
Encino, California
Site status: Not listed — confirm with the team
Collaborative Neuroscience Network, LLC (CNS)
Garden Grove, California
Site status: Not listed — confirm with the team
Synergy San Diego
Lemon Grove, California
Site status: Not listed — confirm with the team
Catalina Research Institute, LLC
Montclair, California
Site status: Not listed — confirm with the team
Pacific Research Partners, LLC
Oakland, California
Site status: Not listed — confirm with the team
NRC Research Institute
Orange, California
Site status: Not listed — confirm with the team
CNRI - Los Angeles
Pico Rivera, California
Site status: Not listed — confirm with the team
CNRI-San Diego, LLC
San Diego, California
Site status: Not listed — confirm with the team
Collaborative Neuroscience Network, LLC (CNS)
Torrance, California
Site status: Not listed — confirm with the team
Meridien Research
Maitland, Florida
Site status: Not listed — confirm with the team
Premier Clinical Research Institute
Miami, Florida
Site status: Not listed — confirm with the team
University of Miami
Miami, Florida
Site status: Not listed — confirm with the team
Apalachee Center
Tallahassee, Florida
Site status: Not listed — confirm with the team
Jerome Golden Center for Behavioral Health
West Palm Beach, Florida
Site status: Not listed — confirm with the team
Synexus
Atlanta, Georgia
Site status: Not listed — confirm with the team
Uptown Research Institute
Chicago, Illinois
Site status: Not listed — confirm with the team
Lake Charles Clinical Trials LLC
Lake Charles, Louisiana
Site status: Not listed — confirm with the team
Cherry Health
Grand Rapids, Michigan
Site status: Not listed — confirm with the team
Center for Behavioral Medicine
Kansas City, Missouri
Site status: Not listed — confirm with the team
Synexus Clinical Research US, Inc.
New York, New York
Site status: Not listed — confirm with the team
UNC Center for Excellence in Community Mental Health, North Carolina Psychiatric Research Center
Raleigh, North Carolina
Site status: Not listed — confirm with the team
Midwest Clinical Research
Dayton, Ohio
Site status: Not listed — confirm with the team
FutureSearch Trials of Dallas, LP
Dallas, Texas
Site status: Not listed — confirm with the team
Pillar Clinical Research, LLC
Richardson, Texas
Site status: Not listed — confirm with the team
Office of Dr. Aqeel Hashmi, MD, PA
Richmond, Texas
Site status: Not listed — confirm with the team
Northwest Clinical Research Center
Bellevue, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving BI 425809, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 50 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Boehringer Ingelheim, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
